Adverse effects of amorphous silica nanoparticles: Focus on human cardiovascular health

Caixia Guo,Yufan Liu,Yanbo Li

DOI: https://doi.org/10.1016/j.jhazmat.2020.124626

2021-03-15

Abstract:Amorphous silica nanoparticle (SiNPs) has tremendous potential for a host of applications, while its mass production, broad application and environmental release inevitably increase the risk of human exposure. SiNPs could enter into the human body through different routes such as inhalation, ingestion, skin contact and even injection for medical applications. The cardiovascular system is gradually recognized as one of the primary sites for engineered NPs exerting adverse effects. Accumulating epidemiological or experimental evidence support the association between SiNPs exposure and adverse cardiovascular effects. However, this topic is still in its infancy, and the literature shows high inter-study variability and even contradictory results. New challenges still present in the safety evaluation of SiNPs, and its toxicological mechanisms are poorly understood. Here, scientific papers related to cardiovascular studies of SiNPs in vivo and in vitro were selected, and the updated particle-caused cardiovascular toxicity and potential mechanisms were summarized. Moreover, the understanding of how factors primarily including exposure dose, route of administration, particle size and surface properties, influence the interaction between SiNPs and cardiovascular system was discussed. In particular, the adverse outcome pathway (AOP) framework by which SiNPs cause deleterious effects in the cardiovascular system was described, aiming to provide useful information necessary for the regulatory decision and to guide a safer application of nanotechnology.